TCT 2023 | EVOLUT Low Risk: 4-Year Follow-up

In recent years, there has been a steady increase in the use of transcatheter aortic valve replacement (TAVR) in younger patients, with an average age of 74 years, as observed in US medical records. This trend goes alongside encouraging durability results, as demonstrated in the 10-year NOTION study, where structural valve degeneration (SVD) with first-generation CoreValve was lower compared with surgery, and the all-cause mortality rate was similar between groups.

TCT 2023 | Estudio WATCH-TAVR

It is important to note that SVD should not be overlooked, as its presence has been associated with nearly double the risk of cardiovascular mortality or rehospitalization.

The purpose of this study was to report on the clinical and hemodynamic follow-up at 4 years for patients who underwent TAVR compared with surgical aortic valve replacement (SAVR), using data from the EVOLUT Low Risk Trial. There was a 94.7% follow-up in the TAVR group and 89.2% in the SAVR group.

There was a mean gradient ≥20mmHg in 4% of all TAVR patients compared with 8.9% of all SAVR patients (p=0.002). The prosthetic mismatch was lower (1.1% vs. 3.5%; p=0.008). When evaluating the primary clinical endpoint (all-cause mortality or disabling stroke), there was a 26% reduction (hazard ratio [HR]=0.74, 95% confidence interval [CI], 0.54-1.00; Log-rank p = 0.05), primarily due to a reduction in all-cause mortality (HR, 0.74; 95% CI, 0.53-1.03; Log-rank p = 0.07).

In terms of paravalvular regurgitation (PVR), there were no significant differences in terms of moderate or severe PVR (p = 0.50). PVR was most frequently trivial (84.7%) or mild (14.9%) in the TAVR group. Additionally, the hemodynamic performance was better in patients in the TAVR group, with lower effective orifice area and mean gradients (p < 0.001). In terms of safety, the TAVR group had a higher pacemaker implantation rate (24.6% vs. 9.9%; p<0.001).

Read also: TCT 2023 | SWISS-APERO: One-Year Events After Left Atrial Appendage Closure with Amulet or Watchman FLX Device.

In summary, patients who underwent TAVR had lasting results in follow-up, with superior hemodynamic profiles compared with SAVR. Event curves continued to show a divergent trend over the years, favoring TAVR. These results suggest that, in low-risk patients, the Evolut platform should be considered as a preferred option, in light of the aforementioned results.

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.

Presented by Michael J. Reardon in Late-Breaking Clinical Trials at TCT 2023, San Francisco, October 23, 2023.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

Left Bundle Branch Block after TAVR: What Is Its Impact?

Courtesy of Dr. Juan Manuel Pérez. Left bundle branch block (LBBB) is a common complication following transcatheter aortic valve replacement (TAVR), which can be either...

Multicenter Experience with 3D Intracardiac Echocardiography for Guiding Interventional Cardiac Procedures

Courtesy of Dr. Juan Manuel Pérez. Imaging techniques play a fundamental role in interventional cardiac procedures. Intracardiac echocardiography (ICE) appears as an alternative to transesophageal...

Pathology of Self-Expanding Transcatheter Aortic Bioprostheses and Hypoattenuated Leaflet Thickening

Courtesy of Dr. Juan Manuel Pérez. Despite the available long term followup data on of transcatheter aortic valve replacement (TAVR), bioprosthesis durability continues under debate....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...